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OBJECTIVE—The incretin glucagon-like peptide 1 (GLP-1)
exerts insulinotropic activity in type 2 diabetic patients, whereas
glucose-dependent insulinotropic polypeptide (GIP) no longer
does. We studied whether GIP can alter the insulinotropic or
glucagonostatic activity of GLP-1 in type 2 diabetic patients.
RESEARCH DESIGN AND METHODS—Twelve patients with
type 2 diabetes (nine men and three women; 61 6 10 years; BMI
30.0 6 3.7 kg/m
2; HbA1c 7.3 6 1.5%) were studied. In randomized
order, intravenous infusions of GLP-1(7-36)-amide (1.2 pmol $
kg
21 $ min
21), GIP (4 pmol $ kg
21 $ min
21), GLP-1 plus GIP,
and placebo were administered over 360 min after an overnight
fast ($1 day wash-out period between experiments). Capillary
blood glucose, plasma insulin, C-peptide, glucagon, GIP, GLP-1,
and free fatty acids (FFA) were determined.
RESULTS—Exogenous GLP-1 alone reduced glycemia from 10.3
to 5.1 6 0.2 mmol/L. Insulin secretion was stimulated (insulin,
C-peptide, P , 0.0001), and glucagon was suppressed (P = 0.009).
With GIP alone, glucose was lowered slightly (P = 0.0021); insulin
and C-peptide were stimulated to a lesser degree than with GLP-1
(P , 0.001). Adding GIP to GLP-1 did not further enhance the
insulinotropic activity of GLP-1 (insulin, P = 0.90; C-peptide, P =
0.85). Rather, the suppression of glucagon elicited by GLP-1 was
antagonized by the addition of GIP (P = 0.008). FFA were sup-
pressed by GLP-1 (P , 0.0001) and hardly affected by GIP (P =
0.07).
CONCLUSIONS—GIP is unable to further amplify the insulino-
tropic and glucose-lowering effects of GLP-1 in type 2 diabetes.
Rather, the suppression of glucagon by GLP-1 is antagonized by
GIP. Diabetes 60:1270–1276, 2011
A
bnormalities in the secretion and insulinotropic
activity of incretin hormones like gastric inhib-
itory polypeptide (also called glucose-dependent
insulinotropic polypeptide [GIP]) and glucagon-
like peptide 1 (GLP-1) have been described in patients with
type 2 diabetes (1–4). In particular, GIP has been found
to no longer potently stimulate insulin secretion in type 2
diabetes (5–7), even at high, supraphysiological doses/
concentrations (7). This appears to be a problem of all
types of diabetes (3,4), independent from their pathogen-
esis, and, therefore, has been blamed upon the common
element, hyperglycemia (8). Although some recent studies
have attempted to elucidate the mechanisms whereby
hyperglycemia attenuates GIP receptor expression and the
responsiveness of insulin secretory activity to GIP in the
diabetic state (8,9), the phenomenon of a reduced insu-
linotropic activity in patients with type 2 diabetes is still not
fully understood.
In contrast, GLP-1 is able to stimulate insulin secretion
in type 2 diabetes (10–13) and has become the parent
compound for the development of incretin-based antidia-
betic drugs (14). This difference in the insulinotropic ac-
tivity of the two incretins in patients with type 2 diabetes is
a surprise, since the cellular mechanisms triggering insulin
secretion are the same for both GIP and GLP-1 (15).
Nevertheless, in animal experiments, GIP or its peptide
analogs have been explored as glucose-lowering agents
with some success (16–22), although none of these analogs
has ever been developed as an antidiabetic drug for type 2
diabetes. It has become clear that GIP administered acutely
does not augment insulin release to any great degree in
patients with type 2 diabetes (6,7,23). This does not exclude
am o d i ﬁcation of insulin secretory activity primarily stimu-
lated by other agents, as recently demonstrated for the
coadministration of GIP and sulfonylureas (24). Thus we
were interested in testing for a potential interaction be-
tween GIP and GLP-1, both administered exogenously, in
patients with type 2 diabetes, especially because these
incretin hormones interact in an additive manner in healthy
human subjects (25). Preliminary results have been pub-
lished in abstract form (26).
RESEARCH DESIGN AND METHODS
Study protocol. The study protocol was approved by the ethics committee of
the Georg-August-Universität Göttingen on 9 June 2008 (registration number:
14/3/01) before the study. Written informed consent was obtained from all
participants.
Patients. Twelve patients with type 2 diabetes were examined. Their char-
acteristics are summarized in Table 1.
Design of the study. All participants underwent a screening examination and
four additional tests on different days in randomized order. All antidiabetic
medications (insulin and oral antidiabetic drugs) were discontinued 1 day
before each experiment, and experiments were started in the morning after an
overnight fast. Either placebo (vehicle: 0.9% NaCl with 1% human serum al-
bumin), GIP (4 pmol $ kg
21 $ min
21), GLP-1(7-36)-amide (1.2 pmol $ kg
21 $
min
21), or a combination of both incretin hormones was infused over 360 min.
This pharmacological dose of GLP-1 has previously been used to normalize
fasting glycemia in patients with type 2 diabetes without side effects (10,11).
The dose of GIP was expected to result in clearly high, pharmacological
concentrations. In previous studies, even higher doses of GIP had been used
(7), so that the dose chosen could be considered safe. Plasma glucose con-
centrations, parameters characterizing insulin secretion (insulin, C-peptide,
insulin secretion rates determined by deconvolution analysis), glucagon, and
free fatty acids were determined in blood drawn in the basal state and during
the infusions. As a minimum, a day without study-related activities (normal
eating rhythm, administration of usual antidiabetic treatment; Table 1) was
allowed between experiments.
Human synthetic GLP-1 and GIP. Human synthetic GLP-1 and GIP (GMP
grade, for human use) were obtained from PolyPeptide, Wolfenbüttel,
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ORIGINAL ARTICLEGermany, and prepared for the administration to human subjects by Pegasus
Pharma, Hannover, Germany. This included sterile ﬁltration, lyophylization,
and packaging into sterile glass vials (GIP, 300 mg per vial; GLP-1, 150 mg per
vial), labeling and analysis (amino acid composition and sequence, purity,
solvent residues, sterility, etc.) and repeated examinations for stability. GIP
and GLP-1 vials were stored in a refrigerator (4°C), opened for the experi-
ments, and dissolved in vehicle (0.9% NaCl with 1% human serum albumin;
Behring, Marburg, Germany, 20%, Lot. No. 5494441A). The concentration was
calculated to allow for a common infusion rate (4 mL/h), adjusting for dif-
ferences in body weight.
Blood specimens. Blood was drawn into chilled tubes containing EDTA
and aprotinin (Trasylol; 20,000 KIU/mL, 180 mL per 9 mL blood; Bayer AG,
Leverkusen) and kept on ice. A capillary sample taken from hyperemic ear
lobes (Finalgon = Nonivamid 4 mg/g, Nicoboxil 25 mg/g) (;100 mL) was stored
in NaF (Microvette CB 300; Sarstedt, Nümbrecht, Germany) for the immediate
measurement of glucose. After centrifugation at 4°C, plasma for hormone
analyses was divided into aliquots of 0.5 or 1 mL and stored frozen at 230°C.
Laboratory determinations. Glucose was measured using a glucose oxidase
method with a Glucose Analyzer 2 (Beckman Instruments, Munich, Germany).
Insulin and C-peptide were determined by speciﬁc immunoassays as pre-
viously described (27). The concentrations of total GIP and GLP-1 were
measured as previously reported (28,29).
Intact, biologically active GIP was measured as described (29) using an
antiserum reacting with the NH2-terminal portion of GIP. The experimental
detection limit was ,2 pmol/L. Intra- and interassay coefﬁcients of variation
are ,6a n d,12%, respectively.
Concentrations of intact, biologically active GLP-1 (sequence 7-36-amide)
were determined using a sandwich radioimmunoassay as described (30). The
experimental detection limit was ,0.5 pmol/L. Intra- and interassay coef-
ﬁcients of variation are 2 and 5%, respectively.
Pancreatic glucagon was measured using porcine antibody 4305 in ethanol-
extracted plasma, as previously described (31). The detection limit was
,1 pmol/L. Intra-assay coefﬁcients of variation were 6%, and interassay
coefﬁcients of variation were 16%.
Free fatty acids were assayed using reagents from Wako Chemicals, Neuss,
Germany, on a Siemens (Dade Behring) Dimension Xpand Autoanalyser.
Statistics. Subject characteristics are reported as means 6 SD. Results are
reported as means 6 SE. Integration was carried out using the trapezoidal
rule. Integrated incremental responses describe changes above baseline; in-
tegrated decrements describe changes below baseline.
Insulin secretion rates were calculated from C-peptide concentrations using
software ISEC version 3.4a, supplied by Dr. Roman Hovorka, London, U.K.
Population-derived coefﬁcients of transition between compartments were used
as described (32–35).
Steady-state concentrations of incretin hormones were calculated as mean
values between 60 and 360 min. Metabolic clearance rates for GLP-1 and GIP
(total concentrations) were calculated dividing nominal infusion rates (per
kilograms body wt and minute) by steady-state concentrations.
Repeated-measures ANOVA (Statistica 5.0; Statsoft, Tulsa, AZ) was per-
formed on all parameters determined over the whole duration of the experi-
ments. Independent variables were experimental conditions (placebo, GIP,
GLP-1, or combined administration), patient (random variable), and time (ﬁxed
effects). As results, P values for treatment effects, changes with time, and their
interaction are reported in the ﬁgures. If a signiﬁcant difference regarding
treatment, or a signiﬁcant interaction of these treatment effects with time (P ,
0.05), was documented, results at single time points were compared by one-
way ANOVA, using the same independent variables; if P values were ,0.05,
this was followed by Duncan post hoc test to identify differences at individual
time points between any of the treatments.
For integrated incremental or decremental changes, one-way ANOVA was
used. In case of an overall signiﬁcant difference (P , 0.05), Duncan post hoc
test was used to identify differences between the groups.
P values ,0.05 were taken to indicate signiﬁcant differences.
RESULTS
Patients. Type 2 diabetic patients with fasting hypergly-
cemia were recruited for the current study. Hyperglycemia
was more pronounced after discontinuing the antidiabetic
medication for 1 day before each experiment (P = 0.04;
Table 1).
Glucose. Plasma glucose concentrations slightly fell with
placebo administration over the duration of the experi-
ments (Fig. 1). With exogenous GIP, a slight reduction in
glucose concentrations was observed. GLP-1, on the other
hand, led to a normalization of glucose concentrations
within 4 h, and normoglycemic values were maintained for
the remainder of the experiment. The addition of GIP did
not further lower glucose concentrations, nor was the re-
duction in glycemia observed earlier (Fig. 1). Integrated
decremental glucose concentrations (Table 2) conﬁrm the
potent glucose-lowering activity of GLP-1 and the lack of
activity of GIP, alone or in combination with GLP-1.
GIP and GLP-1 concentrations. Exogenous GIP ele-
vated plasma concentrations of total and intact GIP, to
steady-state levels of ;530 pmol/L for the total concen-
trations and 225 pmol/L for the concentrations of intact,
biologically active GIP (Fig. 2). The coadministration of
GLP-1 did not change the steady-state concentrations or
metabolic clearance rate of GIP (Table 3). Exogenous
GLP-1 elevated plasma concentrations of total and intact
GLP-1, to steady-state levels of ;145 pmol/L for the total
concentrations and 20 pmol/L for the concentrations of
intact, biologically active GLP-1. The coadministration
of GLP-1 did not change the steady-state concentrations or
metabolic clearance rate of GLP-1 (Table 3).
Insulin secretory activity. Based on the analysis of in-
sulin and C-peptide concentrations as well as insulin se-
cretory rates, GLP-1 was able to potently stimulate insulin
secretion, whereas GIP hardly did so (Fig. 1). Integrated
increments in C-peptide were stimulated approximately
threefold more with GLP-1 than with GIP (P = 0.02), and
TABLE 1
Subject characteristics of type 2 diabetic patients participating in
the study
Parameter Number Mean 6 SD Range
Sex (female/male) 3/9
Age (years) 61 6 10 43–74
Duration of diabetes
(years) 7 6 62 –22
HbA1c (%) 7.3 6 1.5 6–11.4
BMI (kg/m
2) 30.0 6 3.7 24–33
Blood pressure (mmHg)
Systolic 139 6 10 120–160
Diastolic 81 6 57 2 –90
Creatinine (mg/dL) 0.9 6 0.2 0.7–1.1
Cholesterol (mg/dL)
Total 205 6 51 135–297
LDL 123 6 46 34–222
HDL 46 6 10 30–55
Metformin (number, dose
[mg/day]) 8 2,200 6 378 2,000–3,000
Glibenclamide (number,
dose [mg/day]) 3 4.7 6 2.0 3.5–7.0
Bedtime insulin (number,
dose [IU/day]) 1 16 16
Intensive insulin therapy
(number, dose [IU/day]) 3 47.7 6 40.0 16–103
Nephropathy 1
Neuropathy 3
Retinopathy 0
Macroangiopathy 2
Hypertension 9
Fasting plasma glucose at
screening (mmol/L) 8.2 6 1.7 6.5–11.0
Fasting plasma glucose after
antidiabetic therapy
discontinuation (mmol/L) 10.1 6 2.9 8.5–17.0
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was approximately sixfold. The same pattern resulted
from analyses of insulin secretory rates determined by
deconvolution (Fig. 1).
Glucagon. Glucagon concentrations were suppressed
signiﬁcantly by exogenous GLP-1, whereas they tended to
increase slightly with exogenous GIP (Fig. 3). Remarkably,
the coadministration of GIP together with GLP-1 blunted
the suppression of glucagon by GLP-1, which was no lon-
ger signiﬁcant in the presence of elevated GIP concen-
trations.
Nonesteriﬁed fatty acids. Exogenous GLP-1 signiﬁcantly
reduced plasma concentrations of free fatty acids (Fig. 3),
whereas exogenous GIP did not alter levels of free fatty
acids, whether administered alone or in combination with
GLP-1.
Adverse events. No nausea or vomiting, or any other
signiﬁcant side effect, was reported by any of the patients
during or after the exogenous (intravenous) administration
of GLP-1 and/or GIP.
DISCUSSION
Although pharmacological concentrations (approximately
four- to sixfold higher than peak concentrations after nu-
trient stimulation [36,37]) of GLP-1 potently can augment
FIG. 1. Concentrations of capillary plasma glucose (A), and venous plasma concentrations of insulin (B), and C-peptide (C), and insulin secretion
rates derived by deconvolution analysis (D) over 360 min of intravenous infusions of placebo (gray circles), GIP (blue circles), GLP-1 (green circles),
or the combination of GIP and GLP-1 (red circles). Data are means 6 SE. Statistical analysis was done by repeated-measures ANOVA (A, by group; B,
by time; AB, interaction of group assignment and time). Symbols (see key) indicate signiﬁcant differences between speciﬁc experiments. Deﬁnitions of
symbols in A and D also apply to symbols in B and C.
TABLE 2
Integrated incremental or decremental glucose, insulin, C-peptide, insulin secretion rates (deconvolution), glucagon, and free fatty
acid concentrations after intravenous placebo, GLP-1, GIP, or GLP-1 plus GIP infusions in type 2 diabetic patients
Parameter
Relation to
baseline Placebo GLP-1 GIP
GLP-1 plus
GIP
Signiﬁcance
(P value)
Glucose (mmol $ L
21 $ min) Below 2571 6 85
b 21,370 6 151
a,c 2735 6 93
b 21,230 6 140
a,c ,0.0001
Insulin (mU $ L
21 $ min) Above 0.7 6 0.3 13.9 6 6.7 2.1 6 0.6 12.6 6 4.9 0.015
C-peptide (nmol $ L
21 $ min) Above 12.9 6 4.3
b 141.0 6 35.3
c 54.1 6 12.5 142.9 6 32.0b
a,c ,0.0001
Insulin secretion (pmol/kg body wt) Above 82 6 48 367 6 80
a,c 145 6 34 321 6 71
a 0.002
Glucagon (pmol $ L
21 $ min) Below 21,111 6 149
c 21,392 6 232
c 2554 6 146
b,a 2871 6 182
b 0.001
Nonesteriﬁed fatty acids
(mmol $ L
21 $ min) Below 28 6 4
b 234 6 8
a,c 211 6 3
b 234 6 8
c 0.0002
aSigniﬁcant difference (P , 0.05) to placebo.
bSigniﬁcant difference (P , 0.05) to GLP-1.
cSigniﬁcant difference (P , 0.05) to GIP.
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leading to a normalization of plasma glucose concen-
trations within 4 h, GIP has only marginal effects on insulin
secretion, with little consequence for glucose concen-
trations. These results conﬁrm previous results, both with
GLP-1 (10,11) and with GIP (5–7). The novel ﬁnding of our
present study is the ﬁnding that coadministration of GIP in
addition to GLP-1 does not further augment insulin se-
cretory activity in patients with type 2 diabetes. Rather, the
glucagon-suppressing activity of GLP-1 is counteracted by
the simultaneous presence of high GIP concentrations
(Fig. 3), in line with previous ﬁndings linking GIP to a
stimulation of glucagon release (38). This could be because
of the fact that GIP, like GLP-2, can directly stimulate the
a-cell, whereas the GLP-1 effect to lower glucagon is in-
direct (via somatostatin). Apparently, these two mecha-
nisms compete with each other, thus producing the effect
observed (39). Similar mechanisms may be active in re-
sponse to GLP-1 (suppression) and GIP (stimulation) in the
current study.
The lack of interaction of GLP-1 and GIP in the stimu-
lation of insulin secretion in patients with type 2 diabetes
is in sharp contrast with similar experiments performed in
healthy subjects (25) or islets from nondiabetic rodents
(40), where an additivity of the insulinotropic effectiveness
of GLP-1 and GIP has been described. It is not clear
FIG. 2. Concentrations of GIP (total concentrations; A), intact GIP (B), GLP-1 (total concentrations; C), and intact GLP-1 (D) over 360 min of
intravenous infusions of placebo (gray circles), GIP (blue circles), GLP-1 (green circles), or the combination of GIP and GLP-1 (red circles). Data
are means 6 SE. Statistical analysis was done by repeated-measures ANOVA (A, by group; B, by time; AB, interaction of group assignment and
time). At all time points, GIP and GLP-1 concentrations were signiﬁcantly elevated during infusion of the respective peptides.
TABLE 3
Steady-state concentrations and metabolic clearance rates for GLP-1 and GIP infused alone or in combination
Incretin
Steady-state
concentration (pmol/L)
Signiﬁcance
(P value)
Metabolic clearance rate
(mL $ kg
21 $ min
21)
Signiﬁcance
(P value)
GLP-1 0.36 0.50
Alone 155 6 24 15.4 6 7.4
With GIP 132 6 12 10.0 6 1.0
GIP 0.69 0.34
Alone 533 6 23 8.0 6 0.6
With GLP-1 526 6 33 8.0 6 0.6
Data are means 6 SE. The analysis is based on total GLP-1 and GIP concentrations (RESEARCH DESIGN AND METHODS). Metabolic clearance rates
were calculated by dividing infusion rates (pmol $ kg
21 $ min
21) by steady-state concentrations (60–360 min) (pmol/L) (Fig. 2).
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level or just the simultaneous activity of two independent
processes. One possible explanation for the inability of
GIP to augment the insulinotropic response to GLP-1 could
be that the degree of stimulation was close to maximum
with the dose of GLP-1 chosen alone, not allowing any
further stimulation over and above what was observed
with GLP-1. This, however, seems unlikely, since higher
doses of GLP-1 have been able to elicit greater responses
in published studies (41,42).
If physiological concentrations of GIP and GLP-1 were
tested in healthy subjects, the majority of the insulin re-
lease in healthy subjects appeared to be because of GIP
(25), whereas in other studies GLP-1 displayed a similar
potential (43). However, in the experiments in type 2 di-
abetic patients described in the current study, GIP obviously
could not contribute to insulin secretion to any signiﬁcant
extent. According to our study design, antidiabetic drugs
were withdrawn to allow for a permissive degree of hy-
perglycemia, which should support the demonstration of
antidiabetic actions of incretin hormones (10,44). Because
hyperglycemia itself or any variation in the level of glyce-
mia per se may play a role in the desensitization of the
endocrine pancreas to GIP, this may, on the other hand,
have precluded a better response to GIP. Additional
experiments using patients made more normoglycemic at
the time of stimulating insulin secretion may be helpful in
that respect. It would also be of interest to study a more
comprehensive dose range spanning from physiological to
high pharmacological doses of GIP to more fully exclude
any activity in type 2 diabetic patients.
It is important to note that the present experiments were
performed in overnight-fasted patients with type 2 diabetes
and that the results should not be extrapolated to the
postprandial state, in which the deceleration of gastric
emptying plays an important role regarding glucoregulatory
actions of GLP-1 (45), but not GIP (46). Of interest, exog-
enous GIP has recently been described to worsen glycemic
control after meal ingestion in patients with type 2 di-
abetes (47).
The doses and concentrations of both GLP-1 and GIP
used in the current study were clearly supraphysiological.
Regarding GIP, even higher doses (up to 16 pmol $ kg
21 $
min
21 [7]) have been used and were also found to be in-
effective with respect to the stimulation of insulin secre-
tion in patients with type 2 diabetes. When comparing the
steady-state concentrations of intact (both COOH- and
NH2-terminal intact, full biological activity) versus total
(including dipeptidyl peptidase-4 [DPP-4]–mediated deg-
radation products) GIP and GLP-1, it is obvious that GLP-1
is the better substrate for DPP-4, with approximately one
eighth remaining intact during continuous administration,
as in previous studies (48). The corresponding ﬁgure for
GIP is 40% remaining intact (29). GLP-1 and GIP do not
interfere with each other’s degradation or elimination in
type 2 diabetic patients, as previously described in healthy
subjects (Fig. 2 [25]). It also should be noted that the
degree of normalization in fasting glycemia that can be
achieved with exogenous GLP-1 is greater with intra-
venously infused GLP-1 in the current study and in previous
publications (10,11), than typically can be achieved with the
subcutaneous administration of GLP-1 receptor agonists
approved for the treatment of type 2 diabetes (14).
The present results do not encourage the use of GIP as
an antidiabetic agent meant to acutely lower glycemia in
patients with type 2 diabetes. The fact that GIP and some
of its analogs with presumed longer half-lives did improve
the control of glycemia in rodent models of type 2 diabetes
(16,18,19,21,49–52) may be because of the fact that the
insulinotropic activity of GIP appears not to be impaired to
the same degree as in human type 2 diabetes (53). Thus
GIP analogs with promising results in rodents need to be
tested in human patients before their value as potential
antidiabetic agents can be estimated.
Limitations of our study are the rather small number of
patients studied (however, with a very uniform result in all
of them), the short duration of exposure to GIP (6 h), and
the lack of patients with glucose concentrations closer to
normal values. Because the incretin effect seems to be
impaired once fasting glucose concentrations exceed 6
mmol/L (3,4), one could speculate that this provides in-
direct evidence that GIP only effectively stimulates insulin
secretion when the fasting glucose concentrations remain
below this threshold value. A recent study by Højberg et al.
(54) showed an improvement in insulinotropic activity of
GIP after an attempt to normalize glycemia with an in-
tensiﬁed insulin regimen over 4 weeks. Nevertheless, the
improvement in the response to GIP was small in size and,
moreover, the antidiabetic treatment did not result in fasting
glucose concentrations reaching a target of 6 mmol/L. It re-
mains to be seen whether a more effective glucose-lowering
FIG. 3. Concentrations of glucagon (A) and free fatty acids (B)o v e r
360 min of intravenous infusions of placebo (gray circles), GIP (blue
circles), GLP-1 (green circles), or the combination of GIP and GLP-1
(red circles). Data are means 6 SE. Statistical analysis was done by
repeated-measures ANOVA (A, by group; B, by time; AB, interaction of
group assignment and time). Symbols (see key) indicate signiﬁcant
differences between speciﬁc experiments. Deﬁnitions of symbols in A
also apply to symbols in B.
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a greater extent or whether speciﬁc ways of lowering
glucose concentrations (e.g., with GLP-1 or incretin-based
medications) will trigger an improvement in how type 2
diabetic b-cells respond to GIP.
Assuming that GIP does not further potentiate the
insulinotropic effects of GLP-1 and even antagonizes its
glucagonostatic effects, the question arises why the DPP-4
inhibitors still exert potent effects on insulin and glucagon
secretion although they raise the plasma levels of both
incretin hormones. This apparent paradox might be re-
solved by the different GIP plasma levels achieved during
GIP infusion in this study and during DPP-4 inhibitor
treatment. Thus the intact GIP levels reached during DPP-4
inhibitor administration may not sufﬁce to counteract the
potent glucagonostatic effects of GLP-1. Nevertheless, in
light of the present results it seems unlikely that raising
GIP levels plays a relevant role for the antidiabetic actions
of DPP-4 inhibitors.
In conclusion, GIP at a high, pharmacological dose does
not augment insulin secretory responses to GLP-1, nor does
it lead to more rapid lowering in glucose concentrations.
The apparent counteraction of the glucagonostatic activity
of GLP-1 is an adverse response of adding GIP to GLP-1 in
terms of antidiabetic treatment. Taken together, our study
testing the acute exposure to GLP-1 and GIP does not
support any therapeutic effect of GIP in type 2 diabetic
patients, both when administered as a single agent or in
combination with GLP-1.
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